Navigation Links
Palatin Technologies to Present at Windhover's Therapeutic Area Partnerships Conference
Date:11/30/2011

CRANBURY, N.J., Nov. 30, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced that Dr. Carl Spana, President and Chief Executive Officer, will be presenting at Windhover's Therapeutic Area Partnerships conference on Thursday, December 1, 2011.  The conference will be held at the Westin Copley Place in Boston, MA.  Dr. Spana will be presenting an overview on Palatin's Phase 2b trial for bremelanotide in premenopausal women with female sexual dysfunction, and the Phase 1 trial for AZD2820, under development for the treatment of obesity, in collaboration with AstraZeneca.  Bremelanotide, the Company's lead drug candidate, was named one of the "2011 Top Projects to Watch" by Windhover.

ABOUT THE CONFERENCE

Windhover's Therapeutic Area Partnerships conference is a uniquely focused meeting among R&D, financing and business development leadership to improve the partnering process and encourage innovative thinking about productivity and dealmaking. For more information on the conference and presenting companies please go to http://www.tapartnerships.com.  

ABOUT PALATIN TECHNOLOGIES, INC.

Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at http:/
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
2. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
3. Palatin Technologies to Present at 10th Annual BIO Investor Forum
4. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2011 Results
5. Palatin Technologies, Inc. to Report Fiscal Year 2011 Fourth Quarter Results; Teleconference and Webcast to be held on September 22, 2011
6. Palatin Technologies, Inc. to Present at the Rodman & Renshaw Annual Global Investment Conference
7. Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca
8. Palatin Technologies, Inc. Announces Presentation and Publication on Validation of Scale for Subjective Male Sexual Arousal
9. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results
10. Palatin Technologies, Inc. Announces Results of Annual Stockholders Meeting
11. Palatin Technologies, Inc. to Present at the ROTH 23rd Annual OC Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2013 was a banner year of ... They saw continued independent research led by the team ... a $1 million grant from the Susanne Marcus Collins ... a peer reviewed journal, Amy Grant highlighted Brainwave Optimization® ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that they ... Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ... , Turkey and other members ... antibiotic for the treatment of bacterial infections including those ...
(Date:1/14/2014)... January 14, 2014 Histogen, Inc., a ... of cells grown under simulated embryonic conditions, today announced ... with Suneva Medical, Inc. for physician-dispensed aesthetic products containing ... , This agreement is an amendment to the existing ...
(Date:1/14/2014)... NY (PRWEB) January 14, 2014 EquitiesIQ, ... Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical ... serve the wound care market. , Free report download: ... restructured with a seasoned management team and Board, which ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... ... ... -- MODA Technology Partners will offer a live, interactive Webinar on the benefits and value ... 9:00 AM MT). The presentation will feature Marvin Thompson, Manager, Quality Operations at Talecris, and ...
... U.S. Department of Energy,s Argonne National Laboratory will ... in Electrochemical Energy Storage Beyond Lithium Ion: Computational ... electronics and renewable energy applications. Registration ... next generation of high-performance battery technologies is likely ...
... ... MM-111 breast cancer study in combination with trastuzumab. , ... Cambridge, MA (PRWEB) April 17, 2010 -- Merrimack ... the two lead candidates in the company’s pipeline of five novel cancer antibodies, at ...
Cached Biology Technology:Live Webinar: Paperless QC Micro Implemented by Talecris Biotherapeutics 2Live Webinar: Paperless QC Micro Implemented by Talecris Biotherapeutics 3Merrimack to Present Pre-Clinical Data on MM-121 and MM-111 at the 101st Annual Meeting of American Association for Cancer Research (AACR) 2Merrimack to Present Pre-Clinical Data on MM-121 and MM-111 at the 101st Annual Meeting of American Association for Cancer Research (AACR) 3
(Date:7/9/2014)... Calif. Sexual selection refers to species, selection for ... special type of natural selection enhances opportunities to mate, ... , Biologists at the University of California, Riverside have ... formation of a placenta are linked. Describing the ... in the family Poeciliidae, the researchers found that species ...
(Date:7/9/2014)... nature,s ability to split the water molecule during ... artificial photosynthesis for clean, green and renewable energy ... scientists led by researchers with the Lawrence Berkeley ... Accelerator Laboratory. , Working at SLAC,s Linac ... x-ray laser, the researchers were able to take ...
(Date:7/9/2014)... studying critically ill children with traumatic injuries have ... are likely to develop a hospital-acquired infection. The ... and published online in June in the journal ... efforts that could lead to the clinical implementation ... prevent or reverse immune system damage following critical ...
Breaking Biology News(10 mins):Biologists link sexual selection and placenta formation 2Biologists link sexual selection and placenta formation 3Biologists link sexual selection and placenta formation 4Postcards from the photosynthetic edge 2Postcards from the photosynthetic edge 3Immune function predicts infection risk among child trauma patients 2Immune function predicts infection risk among child trauma patients 3
... lesson or two from tiny cells on how to maximize ... at Chicago have found that intra-cellular trafficking is tightly coordinated ... on a crowded road are allowed to pass quickly through ... molecular mechanism that underlies this coordination is reported by lead ...
... for over 50 years that moths can hear the ultrasonic ... are among the simplest in the insect world—they have only ... Previously, it was thought that these ears were only partially ... it would seem likely that by using high ultrasound, bats ...
... a medical case of Jekyll and Hyde, carbon monoxide ... faulty heating systems ?has proven effective in treating the ... condition that typically leads to right heart failure and ... animal study led by researchers at Beth Israel Deaconess ...
Cached Biology News:Molecular mechanism provides intra-cellular traffic signal 2Therapeutic role found for carbon monoxide 2Therapeutic role found for carbon monoxide 3
Recommend to use at 1000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.)...
... kit contains 5 ml CELLection Dynabeads (4.5 ... the human epithelial antigen EpCAM and DNase ... log enrichment of epithelial tumour cells directly ... cells clumps can be enriched from bone ...
... Cy3 Ab Labeling Kit, 1 kit. ... with CyDye fluorescent dyes. Conjugations are ... complete within 1 h. Dyes are ... to ensure consistent labelings. Category: Blotting ...
PHOTOMAN DIRECT COPY CAMERA, 1 EA. Category: Nucleid Acid Detection Systems....
Biology Products: